Sumitomo Mitsui Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $143 Billion
- Q1 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 3,399,318 shares of NTLA stock, worth $72.7 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
3,399,318
Previous 3,478,562
2.28%
Holding current value
$72.7 Million
Previous $106 Million
11.83%
% of portfolio
0.07%
Previous 0.08%
Shares
21 transactions
Others Institutions Holding NTLA
# of Institutions
312Shares Held
89.3MCall Options Held
686KPut Options Held
599K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11MShares$235 Million2.16% of portfolio
-
Black Rock Inc. New York, NY9.11MShares$195 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$194 Million0.01% of portfolio
-
State Street Corp Boston, MA4.6MShares$98.3 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.21MShares$90 Million3.83% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.63B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...